GlassScriptPhysician profile
Olabode Olumofin
NPI 1720025513
$3,554.39
in general payments reported to CMS, 2019-2025
25 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $239 · 2021: $312 · 2022: $349 · 2023: $685 · 2024: $848 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,571 · Travel and Lodging: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,570.69 |
| Travel and Lodging | $393.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $420.15 | 2019-2024 | |
| Medtronic, INC. | $393.12 | 2024 | In.Pact Admiral |
| Abbvie INC. | $390.56 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $341.88 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $312.55 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $199.52 | 2019-2024 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $165.59 | 2024-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $164.58 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $146.21 | 2019-2025 | Verquvo |
| Glaxosmithkline, LLC. | $135.42 | 2019-2022 | |
| Global Blood Therapeutics, INC. | $123.74 | 2022 | |
| Amgen INC. | $95.05 | 2019 | |
| Allergan, INC. | $81.70 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $76.82 | 2025 | |
| Viiv Healthcare Company | $75.80 | 2025 | Apretude |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $73.29 | 2023 | Mitraclip |
| Vertex Pharmaceuticals Incorporated | $70.28 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.32 | 2022 | |
| Boston Scientific Corporation | $62.09 | 2021-2023 | Lux-Dx Insertable Cardiac Monitor |
| Lilly USA, LLC | $50.00 | 2020-2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.49 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $19.90 | 2023 | Inpefa |
| Sunovion Pharmaceuticals INC. | $18.10 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.62 | 2023 | Gvoke Hypopen |
| Sun Pharmaceutical Industries INC. | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olabode Olumofin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.